VELOSEF '250'
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VELOSEF '250' (VELOSEF '250').
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
| Metabolism | Cephradine is predominantly eliminated unchanged by the kidneys via tubular secretion and glomerular filtration. Minimal hepatic metabolism occurs via hydrolysis and N-acetylation. |
| Excretion | Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%) |
| Half-life | 1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD) |
| Protein binding | 20-30% bound to serum albumin |
| Volume of Distribution | 0.2-0.3 L/kg; limited to extracellular fluid; higher in neonates (0.4-0.5 L/kg) |
| Bioavailability | Oral: 80-90% (with food: slightly reduced); Intramuscular: ~100% |
| Onset of Action | Oral: 1-2 hours; Intramuscular: 0.5-1 hour |
| Duration of Action | 6-8 hours (dose-dependent); reduces in severe infection due to increased clearance |
| Molecular Weight | 415.5 |
250 mg orally every 6 hours for adults with normal renal function.
| Dosage form | CAPSULE |
| Renal impairment | CrCl 30-50 mL/min: 250 mg every 8 hours; CrCl 10-29 mL/min: 250 mg every 12 hours; CrCl <10 mL/min: 250 mg every 24 hours. |
| Liver impairment | No specific adjustment required; dose as in normal hepatic function. |
| Pediatric use | Children: 25-50 mg/kg/day in divided doses every 6 hours. |
| Geriatric use | Adjust dose based on renal function; monitor for adverse effects due to age-related decline in renal function. |
| 1st trimester | Generally avoided unless benefit outweighs risk; teratogenic risk low but not well-studied. |
| 2nd trimester | Use with caution; consider alternative if possible. |
| 3rd trimester | Use with caution; theoretical risk of kernicterus in newborns. |
Clinical note
Comprehensive clinical and safety monograph for VELOSEF '250' (VELOSEF '250').
| Placental transfer | Crosses placenta; therapeutic levels achieved in fetal circulation. |
| Breastfeeding | Excreted into breast milk in low concentrations; unlikely to cause adverse effects in infant. Use with caution. |
| Lactation Rating | L2 |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to cephalosporinsAnaphylactic reaction to penicillins (cross-sensitivity risk)
| Precautions | Hypersensitivity reactions (including anaphylaxis, Stevens-Johnson syndrome), Clostridium difficile-associated diarrhea (CDAD), Renal impairment (dose adjustment required), Prolonged use may lead to superinfection, Seizures (especially in patients with renal impairment), Interference with Coombs test and urine glucose tests (false positives) |
| Food/Dietary | No significant food interactions. However, high-fat meals may delay absorption; take on an empty stomach for optimal effect. Avoid alcohol due to potential disulfiram-like reaction. |
Loading safety data…
| Teratogenic Risk | VELOSEF (cephradine) is a first-generation cephalosporin. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. However, cephalosporins are generally considered low risk during pregnancy. No specific fetal risks have been identified in the first, second, or third trimester. FDA Pregnancy Category B. |
| Fetal Monitoring | Standard prenatal monitoring with no specific additional monitoring required. However, monitor for signs of allergic reactions or gastrointestinal disturbances in the mother. No specific fetal monitoring indicated. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impaired fertility. |
| Clinical Pearls |
| Velosef '250' (cephradine) is a first-generation cephalosporin with activity against Gram-positive cocci (except MRSA) and some Gram-negative bacteria. It is renally eliminated; adjust dose in renal impairment. May cause false-positive urine glucose tests (Clinitest) but not with glucose oxidase methods. Use with caution in penicillin-allergic patients due to cross-sensitivity risk. |
| Patient Advice | Take exactly as prescribed, even if you feel better. · Complete the full course to prevent resistance. · May cause diarrhea; notify your doctor if severe or bloody. · Avoid alcohol during treatment and for 72 hours after last dose to reduce risk of disulfiram-like reaction. · Inform your doctor if you are allergic to penicillins or cephalosporins. |